Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -15.83
- Piotroski Score 2.00
- Grade Outperform
- Symbol (KALA)
- Company Kala Pharmaceuticals, Inc.
- Price $5.63
- Changes Percentage (5.17%)
- Change $0.28
- Day Low $5.39
- Day High $5.67
- Year High $10.97
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $15.00
- High Stock Price Target $15.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$14.56
- Trailing P/E Ratio -0.45
- Forward P/E Ratio -0.45
- P/E Growth -0.45
- Net Income $-42,199,000
Income Statement
Quarterly
Annual
Latest News of KALA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Temporary road closures, detours in place on Kalamath Street in Denver this week
RTD in Denver is conducting maintenance work at a light rail crossing on Kalamath Street, leading to a six-day closure with detours. The repairs aim to stabilize the rail base and fix the asphalt. Tem...
By CBS News | 2 weeks ago -
Travis Kalanick reflects on what it was like being ousted from Uber, and why he doesn't 'think about the ex very much'
Uber faced scandals in 2017, leading to tensions between CEO Kalanick and investor Gurley. Amid mounting controversies, Gurley helped oust Kalanick, who left in 2017....
By Business Insider | 2 weeks ago -
Hawaii Travel Update: This Kauai Trail Was Just Named To The Hall Of Fame. No, It's Not The Kalalau Trail.
Kauaʻi's Ke Ala Hele Makālae trail was recently inducted into the Rails to Trails Conservancy Hall of Fame. This 8-mile paved coastal path connects towns and beach parks, offering scenic beauty, com...
By Forbes | 1 month ago
